- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04264741
Transcranial Magnetic Stimulation for Methadone Maintenance Therapy Combined With Methamphetamine Abuse
March 21, 2024 updated by: Shanghai Mental Health Center
Transcranial Magnetic Stimulation for Treating Patients Under Methadone Maintenance Therapy Combined With Methamphetamine Abuse
Repetitive transcranial magnetic stimulation (rTMS) has been used to treat opioid and methamphetamine addiction in previous studies, while no evidence was proved for patients methadone maintenance therapy with methamphetamine abuse.
The aim of this study is to evaluating the effectiveness and safety of rTMS treatment for methamphetamine abuse in patients with methadone maintenance therapy.
Study Overview
Status
Completed
Conditions
Detailed Description
First, a multicenter, double-blind, randomized control study is going to be carried out.
60 recruited patients will be randomized assigned to the intervention group (40) and the control group (20), receiving either 4-week of repetitive transcranial magnetic stimulation (rTMS) treatment or 4-week of sham rTMS treatment.
Both groups will receive 16-week urine drug test (1 time per week, 4 weeks before rTMS, 4 weeks during rTMS and 8 weeks after rTMS).
Self-report methamphetamine use or urine test is set as primary outcome.
Cognitive function and craving are also evaluated before and after the intervention.
Functional magnetic resonance imaging (fMRI) is applied to investigate the potential neurobiological mechanism of rTMS treatment.
This study will be very helpful to develop an evidence-based rTMS treatment protocols for methadone maintenance therapy with methamphetamine abuse and decrease risk of relapse for both the patients and their families.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Haifeng Jiang, PhD
- Phone Number: 021-64906315
- Email: dragonjhf@hotmail.com
Study Locations
-
-
-
Wuhan, China
- Wuhan Mental Health Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Currently in methadone maintenance therapy
- In accordance with the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) for methamphetamine (MA) use disorders
- Junior high school degree or above
- Normal vision and hearing
Exclusion Criteria:
- Have a disease that affect cognitive function such as history of head injury, cerebrovascular disease, epilepsy, etc
- Have cognitive-promoting drugs in the last 6 months
- Other substance abuse or dependence in recent five years (except nicotine)
- Mental impairment, Intelligence Quotient (IQ) < 70
- Mental disorders according to DSM-5 criteria
- Physical diseases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: rTMS treatment group
For rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the iTBS pattern everyday.
Treatment will lasted for 4 weeks.
|
The iTBS group received 900 pulses per day: 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz), 2 s on and 8 s off for 5 min, at 100% resting motor threshold (rMT), over the left DLPFC (F3, EEG system) (4 weeks, 20 daily sessions).
A figure-8-shaped Cool-B70 stimulation coil from MagPro X100 device (MagVenture, Farum, Denmark) was used for accurately targeted stimulation.
Motor threshold was determined over the left motor cortex, by finding the lowest intensity that produced a motor response in the right abductor pollicis brevis muscles (APB), which produced five motor-evoked potentials responses of at least 50 mV in 10 trials.
|
Sham Comparator: sham rTMS treatment group
For sham rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the sham iTBS pattern and sham coil everyday.
Treatment will lasted for 4 weeks.
|
The iTBS group received 900 pulses per day: 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz), 2 s on and 8 s off for 5 min, at 100% resting motor threshold (rMT), over the left DLPFC (F3, EEG system) (4 weeks, 20 daily sessions).
A figure-8-shaped sham Cool-B70 stimulation coil from MagPro X100 device (MagVenture, Farum, Denmark) was used for accurately targeted stimulation.
Motor threshold was determined over the left motor cortex, by finding the lowest intensity that produced a motor response in the right abductor pollicis brevis muscles (APB), which produced five motor-evoked potentials responses of at least 50 mV in 10 trials.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Self-report drug use and urine test
Time Frame: 16 weeks
|
Patients will be asked to report their drug use for 16 weeks every day and do urine tests once a week for 16 weeks.
Loss of visit or rejecting to report or rejecting to do urine tests will be treated as drug use positive (relapse).
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of Craving assessed by Visual Analog Scale
Time Frame: 12 weeks
|
Evaluate all participants' craving for for methamphetamine assessed by Visual Analog Scales (VAS).
Score of VAS range from 0 to 10, and higher values represent high level of craving.
|
12 weeks
|
Cognitive function assessed by Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Time Frame: 12 weeks
|
Evaluate all participants' cognitive function by Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Chinese version
|
12 weeks
|
Functional magnetic resonance imaging
Time Frame: 4 weeks
|
Functional magnetic resonance imaging is collected once before and once after intervention, mainly collecting structural images, resting state, and task-based fMRI
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Haifeng Jiang, PhD, Shanghai Mental Health Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2020
Primary Completion (Actual)
December 31, 2021
Study Completion (Actual)
December 31, 2022
Study Registration Dates
First Submitted
February 9, 2020
First Submitted That Met QC Criteria
February 9, 2020
First Posted (Actual)
February 11, 2020
Study Record Updates
Last Update Posted (Actual)
March 25, 2024
Last Update Submitted That Met QC Criteria
March 21, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- HFJiang-004
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Methamphetamine Abuse
-
National Institute on Drug Abuse (NIDA)Not yet recruitingMethamphetamine-dependence | Methamphetamine Abuse
-
InterveXion Therapeutics, LLCNational Institute on Drug Abuse (NIDA)CompletedMethamphetamine-dependence | Methamphetamine AbuseUnited States
-
University of KentuckyNational Institute on Drug Abuse (NIDA)CompletedMethamphetamine Dependence | Methamphetamine AbuseUnited States
-
Centre for Addiction and Mental HealthNot yet recruitingMethamphetamine-dependence | Methamphetamine AbuseCanada
-
InterveXion Therapeutics, LLCNational Institute on Drug Abuse (NIDA)Active, not recruitingMethamphetamine-dependence | Methamphetamine AbuseUnited States
-
University of KentuckyNational Institute on Drug Abuse (NIDA)CompletedMethamphetamine Dependence | Methamphetamine AbuseUnited States
-
University of California, Los AngelesNational Institute on Drug Abuse (NIDA)TerminatedMethamphetamine Dependence | Methamphetamine AbuseUnited States
-
University of CincinnatiNational Institute on Drug Abuse (NIDA)CompletedMethamphetamine Dependence | Methamphetamine AbuseUnited States, Canada
-
Oregon Health and Science UniversityOregon Health Authority; Comagine HealthRecruitingMethamphetamine AbuseUnited States
-
Assiut UniversityNot yet recruitingMethamphetamine Abuse
Clinical Trials on repetitive transcranial magnetic stimulation (rTMS)
-
Centre Hospitalier Universitaire de NiceCompletedPost-traumatic Stress DisorderFrance
-
MGH Institute of Health ProfessionsNational Institute on Deafness and Other Communication Disorders (NIDCD)Recruiting
-
Centre hospitalier de Ville-Evrard, FranceRecruiting
-
Krystal Parker, PhDRecruitingDepression | Schizophrenia | Parkinson Disease | Bipolar Disorder | Autism Spectrum DisorderUnited States
-
Kaohsiung Veterans General Hospital.RecruitingBipolar II Disorder, Most Recent Episode Major DepressiveTaiwan
-
Brigham and Women's HospitalBeth Israel Deaconess Medical Center; Mclean HospitalNot yet recruitingObesity | Appetitive BehaviorUnited States
-
Yi YangNot yet recruiting
-
Mclean HospitalNational Institute of Mental Health (NIMH); Beth Israel Deaconess Medical CenterRecruitingSchizophrenia | Schizo Affective DisorderUnited States
-
Tehran University of Medical SciencesUnknownBorderline Personality Disorder
-
University of AlbertaRecruitingDepressive Disorder, Treatment-ResistantCanada